XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.19.1

Fair Value Measurements | 3 Months Ended
--- | ---
Mar. 31, 2019
Fair Value Disclosures [Abstract] |
Fair Value Measurement | Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis We estimate the fair value of our Level 1 financial instruments, which are in active markets, using unadjusted quoted market prices for identical instruments. We obtain the fair values for our Level 2 financial instruments, which are not in active markets, from a primary professional pricing source that uses quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Fair values obtained from this professional pricing source can also be based on pricing models whereby all significant observable inputs, including maturity dates, issue dates, settlement dates, benchmark yields, reported trades, broker-dealer quotes, issue spreads, benchmark securities, bids, offers or other market-related data, are observable or can be derived from, or corroborated by, observable market data for substantially the full term of the asset. We validate the quoted market prices provided by our primary pricing service by comparing the fair values of our Level 2 marketable securities portfolio balance provided by our primary pricing service against the fair values of our Level 2 marketable securities portfolio balance provided by our investment managers. The following table summarizes financial assets that we measured at fair value on a recurring basis as of March 31, 2019, classified in accordance with the fair value hierarchy. We sold the equity investment in Tandem Diabetes Care, Inc. that we held as of December 31, 2018 during the first quarter of 2019.
| Fair Value Measurements Using
(In millions) | Level 1 |  | Level 2 |  | Level 3 |  | Total
Cash equivalents | $ | 309.9 |  |  | $ | 49.6 |  |  | $ | — |  |  | $ | 359.5 |
Debt securities, available for sale: |  |  |  |  |  |  |
U.S. government agencies | — |  |  | 54.8 |  |  | — |  |  | 54.8 |
Commercial paper | — |  |  | 3.0 |  |  | — |  |  | 3.0 |
Corporate debt | — |  |  | 15.1 |  |  | — |  |  | 15.1 |
Total debt securities, available for sale | — |  |  | 72.9 |  |  | — |  |  | 72.9 |
Total assets measured at fair value on a recurring basis | $ | 309.9 |  |  | $ | 122.5 |  |  | $ | — |  |  | $ | 432.4 |
The following table summarizes financial assets that we measured at fair value on a recurring basis as of December 31, 2018, classified in accordance with the fair value hierarchy.
| Fair Value Measurements Using
(In millions) | Level 1 |  | Level 2 |  | Level 3 |  | Total
Cash equivalents | $ | 199.3 |  |  | $ | 66.7 |  |  | $ | — |  |  | $ | 266.0 |
Equity investment in Tandem Diabetes Care, Inc. | 38.0 |  |  | — |  |  | — |  |  | 38.0 |
Debt securities, available for sale: |  |  |  |  |  |  |
U.S. government agencies | — |  |  | 173.1 |  |  | — |  |  | 173.1 |
Commercial paper | — |  |  | 36.2 |  |  | — |  |  | 36.2 |
Corporate debt | — |  |  | 1.3 |  |  | — |  |  | 1.3 |
Total debt securities, available for sale | — |  |  | 210.6 |  |  | — |  |  | 210.6 |
Total assets measured at fair value on a recurring basis | $ | 237.3 |  |  | $ | 277.3 |  |  | $ | — |  |  | $ | 514.6 |
There were no transfers between Level 1 and Level 2 securities during the three months ended March 31, 2019 and 2018. There were no transfers into or out of Level 3 securities during the three months ended March 31, 2019 and 2018. We hold certain other investments that we do not measure at fair value on a recurring basis. The carrying values of these investments are not significant and we include them in other assets in our balance sheets. It is impracticable for us to estimate the fair value of these investments on a recurring basis due to the fact that these entities are often privately held and limited information is available. We monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant adverse effect on the fair values. Financial liabilities whose fair values we measure on a recurring basis using Level 1 inputs consist of our outstanding 2022 Notes and 2023 Notes. We measure the fair value of the 2022 Notes and 2023 Notes based on their trading prices. The fair value of the 2022 Notes was $537.5 million as of March 31, 2019 and $540.2 million as of December 31, 2018. The fair value of the 2023 Notes was $876.3 million as of March 31, 2019 and $859.6 million as of December 31, 2018. For more information on the carrying values and fair values of our 2022 Notes and 2023 Notes, see Note 5, “Debt.” Foreign Currency and Derivative Financial Instruments From time to time we engage in limited hedging transactions to reduce foreign currency risks on certain intercompany balances. The fair values of these derivatives are based on quoted market prices, which are Level 1 inputs. As of March 31, 2019, we had no outstanding currency hedging transactions.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -URI http://asc.fasb.org/topic&trid=2155941 + Details
Name: | us-gaap_FairValueMeasurementInputsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration